Pune, India, May 31, 2022 (GLOBE NEWSWIRE) -- The Germany pneumococcal vaccines market size is projected to reach USD 200.9 million by the year 2026. The market will benefit from the increasing number of favorable policies across the region. According to a report published by Fortune Business Insights™, titled “Germany Pneumococcal Vaccines Market Size, Share & Industry Analysis, By Product Type (PCV10, PCV13, and PPSV23), By End User (Hospitals, Clinics, and Others) and Region Forecast, 2019-2026,” the market size was USD 170.0 million in 2018 and will exhibit a CAGR of 2.1% during the forecast period, 2019-2026.
Pneumococcal vaccines are used to prevent pneumonia in paediatrics and adults. The severity of the disease has led to a wider adoption for the product across the world. The demand for pneumococcal vaccines has risen dramatically in the recent years due to the growing emphasis on early detection and treatment of the disease. The growing demand for this product will have a direct impact on the growth of the regional markets in Germany. Variations in product offerings and availability of different vaccines for different disease types will contribute to the growth of the market in the coming years.
Get Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/sample/germany-pneumococcal-vaccines-market-101808
The report encompasses several factors that have contributed to the growth of the market in recent years. It also discusses a few of the factors that have restrained market growth. Besides this, the report highlights a few of the leading products, major companies, and major industry developments of recent times. The Germany Pneumococcal Vaccines Market is segmented on the basis of several criteria, including product types, end users, and regional demographics. The competitive landscape scenario has been discussed in detail. The report provides forecast values for the market for the period of 2019-2026. Factual figures have been obtained through trusted sources. Predictions have been made through interviews and opinions of experienced market research professional.
Pneumococcal vaccines are used in vaccination against the bacteria Streptococcus pneumoniae. Pneumonia is a severe and potentially life-threatening disease that is caused by deadly bacteria. The pneumococcal vaccines are aimed in use for paediatrics as well as adults for treating acute and serious infections that are consequential to pneumonia. The severity of this disease has led to a higher emphasis on early adoption and treatment. Increasing investments on the research and development of newer vaccination options for the disease will bode well for the growth of the market in the coming years. Advances in ongoing clinical trials will bode well for the growth of the market. Increasing number of regulatory approvals, coupled with the growing investments in product R&D will aid the growth of the market in the forthcoming years.
Germany Pneumococcal Vaccines Market Report Scope & Segmentation :
| Report Coverage | Details |
| Forecast Period | 2019 to 2026 |
| Forecast Period 2019 to 2026 CAGR | 2.1% |
| 2029 Value Projection | USD 200.9 Million |
| Base Year | 2018 |
| Market Size in 2018 | USD 170.01 Million |
| Historical Data for | 2016 to 2017 |
| No. of Pages | 90 |
| Segments covered | By Product Type, By End User, Region |
| Growth Drivers | Increasing Awareness Regarding the Severity of this Disease Will Aid Growth |
| Nordrhein-Westfalen to Emerge as the Leading Region; Huge Patient Pool for Pneumonia Will Aid Growth | |
| Pfizer and Merck & Co. Dominate the Market |
Pfizer and Merck & Co. Dominate the Market
The Germany pneumococcal market is consolidated in nature, with only a few players accounting for a high market share. The current pneumococcal polysaccharide vaccines scenario sees Pfizer holding a dominating share. A strong distribution network, combined with the growing prescription of PCV13 for patients, have favored the growth of these companies.
Increasing Awareness Regarding the Severity of this Disease Will Aid Growth
The severity of pneumonia has led to a high awareness among users across the world. Pneumonia can possess several side effects. Unattended pneumonia can also cause death. The increasing prevalence of pneumonia will open up a huge potential for the growth of the market in Germany. As per recent statistics, almost 12% of the patients affected by pneumonia do not survive. This, in turn, has led to a further rise in the demand for pneumococcal vaccines in the country. The presence of several renowned companies will emerge in favor of market growth. Contribution from government through initiatives and awareness programs will contribute to the growth of the market in this region. Recent advances in pipeline drugs will newer drugs. Furthermore, advances in phases of clinical trials of numerous drugs will contribute to the growth of the market in the forthcoming years.
Speak To Our Analyst:
Nordrhein-Westfalen to Emerge as the Leading Region; Huge Patient Pool for Pneumonia Will Aid Growth
The market is segmented on the basis of regional demographics into several regions across Germany into Baden-Württemberg, Bayern, Nordrhein-Westfalen, Hessen, Niedersachsen, Sachsen, and Berlin. The market in Nordrhein-Westfalen is likely to hold the highest Germany pneumococcal vaccines market share in the coming years. The growing prevalence of pneumonia in this region will provide the platforms for the growth of the regional market. Besides Nordrhein-Westfalen, the market has been analysed across several other regions in the country.
A few of the leading companies that are operating in the Germany pneumococcal vaccines market are:
- Pfizer
- Merck & Co. Inc.
- GlaxoSmithKline plc
- Sanofi
Key Industry Developments:
August 2016: The German Committee on Vaccination introduced an update in the German pneumococcal vaccination policy wherein pneumococcal vaccination were recommended through a sequential vaccination scheme.
Quick Buy - Germany Pneumococcal Vaccines Market Research Report:
https://www.fortunebusinessinsights.com/checkout-page/101808
Table Of Contents :
- Germany Pneumococcal Vaccines Market Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Germany Pneumococcal Vaccines Market Drivers
- Germany Pneumococcal Vaccines Market Restraints
- Germany Pneumococcal Vaccines Market Opportunities
- Key Insights
- Pipeline Analysis of Key Global Players
- Pricing Analysis Of Key Products
- Key Mergers and Acquisitions
- Prevalence of Pneumonia in Germany
- Immunization Coverage of Pediatric Patients in Germany
- Germany Pneumococcal Vaccines Market Analysis, Insights and Forecast, 2016-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Product Type
- PCV10
- PCV13
- PPSV23
- Market Analysis, Insights and Forecast – By End User
- Hospitals
- Clinics
- Others
- Market Analysis, Insights and Forecast – By Geography
- Baden-Württemberg
- Bayern
- Nordrhein-Westfalen
- Hessen
- Niedersachsen
- Sachsen
- Berlin
- Others
- Competitive Analysis
-
- Germany Market Share Analysis (2018)
- Comparative Analysis – Major Players
- Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- Pfizer
- Merck & Co. Inc.
- GlaxoSmithKline plc
- Sanofi
Toc Continue..
Ask for Customization of this Report:
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Press Release : https://www.fortunebusinessinsights.com/press-release/germany-pneumococcal-vaccines-market-9456
